Please login to the form below
interferon beta-1a
This page shows the latest interferon beta-1a news and features for those working in and with pharma, biotech and healthcare.
UK biotech Synairgen treats first patient in phase 3 COVID-19 trial
SNG001 delivers an inhaled formulation of Interferon-beta-1a directly to the lungs. ... SNG001 delivers an inhaled formulation of Interferon-beta-1a (INF-beta-1a) to the lungs directly via nebulisation.
Latest news
-
New intramuscular administration for Biogen’s MS therapy Plegridy approved in the EU
Plegridy (peginterferon beta-1a) is a long-acting treatment for RRMS in which interferon beta-1a – the active ingredient in Biogen's Avonex (interferon beta-1a) – is pegylated to make the ... drug last longer in the body than other beta interferons.
-
Synairgen’s SNG001 advances into phase 3 COVID-19 trial
SNG001 delivers an inhaled formulation of Interferon-beta-1a (INF-beta-1a) to the lungs directly via nebulisation – INF-beta is a naturally occurring protein that controls the body’s antiviral ... This pH neutral, inhaled interferon beta-1a
-
Positive COPD data for Synairgen's SNG001 supports COVID-19 programme
placebo. SNG001 delivers an inhaled formulation of Interferon-beta-1a (INF-beta-1a) to the lungs directly via nebulisation and has previously been tested in phase 2 trials in asthma. ... INF-beta is a naturally occurring protein that controls the
-
UK biotech Synairgen reveals promising early results for COVID-19 drug
SNG001 delivers an inhaled formulation of Interferon-beta-1a (INF-beta-1a) to the lungs directly via nebulisation and has previously been tested in phase 2 trials in asthma. ... The results confirm our belief that interferon-beta, a widely known drug that
-
Trump calls on FDA to cut ‘red tape’ as coronavirus drug trials gather pace
Finally, Merck KGaA has donated a supply of its interferon beta-1a product Rebif – approved for multiple sclerosis - to France’s INSERM research organisation following a request for use in a
New intramuscular administration for Biogen’s MS therapy Plegridy approved in the EU
Synairgen’s SNG001 advances into phase 3 COVID-19 trial
UK biotech Synairgen reveals promising early results for COVID-19 drug
Trump calls on FDA to cut ‘red tape’ as coronavirus drug trials gather pace
More from news
Approximately 1 fully matching, plus 57 partially matching documents found.
Latest Intelligence
-
Tackling a formidable foe
Formidable foe. “With Rebif (interferon beta-1a), Merck’s legacy MS therapy approved in Europe 20 years ago, one of the innovations is the ability to have auto-injectors and devices
Tackling a formidable foe
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Senior Consultant, Pricing & Market Access Consultancy, circ...
-
circa £100K package
- Principal/ Senior/ Medical Writer – Global Med Ed and Comms Agen...
-
Highly competitive salary
-
Digital account director
-
Competitive
- Account Manager - Healthcare Consultancy
-
Salary depending on experience
- Project Director, Healthcare Marketing Agency patient focus Lond...
-
Highly competitive salary
- Digital Project Director, Healthcare Marketing Agency patient fo...
-
Highly competitive salary
-
Events Executive
-
Depending on Experience
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
- Mixing AZ and Pfizer COVID-19 vaccines increases antibody levels
- AZ publishes new real-world safety data for COVID-19 vaccine Vaxzevria
- CHMP rejects Kyowa Kirin’s Parkinson’s disease drug
- The Chronicles of Pharma: a creative review of pharma’s journey to omnichannel
- Google’s DeepMind opens ‘breakthrough’ protein database to the world
- Merck & Co’s sales bounce back in ‘ongoing recovery from COVID-19’
- Lilly and Kumquat Biosciences link up in $2bn-plus immuno-oncology deal
- Michael J. Fox Foundation and IBM reveal new AI model for Parkinson’s disease
- BMS’ Q2 results beat expectations with strong performance across core therapy areas
- Amanda Pritchard becomes NHS England’s first female chief executive
- Understanding the ‘real world’ starts and ends with the patient
- Onyx Health Launch Creative Studio After Record Year
- BioNTech plans acquisition of Kite’s TCR cell therapy R&D platform
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
- The Chronicles of Pharma: a creative review of pharma’s journey to omnichannel
- Tonix Pharmaceuticals to develop TNX-102 for long COVID syndrome
- Migraine-friendly colours for the home
PMHub
Havas Lynx Group
We are the Havas Lynx Group. Devoted to fresh thinking. Changing the way the world does healthcare communications for the...
Latest intelligence
- Top 10 ways to leverage the Impetus InSite Platform® to (virtually) launch your brand
- The Impetus InSite Platform® can be used to facilitate virtual and hybrid engagement at all stages of the product lifecycle. Here, we share 10 of the most popular ways to...
- Employee wellbeing in creative agencies: three tips to get you started
- Paul Hutchings, founder of fox&cat, and new friend, Welfy, a workplace wellbeing training firm, discuss the importance of collaboration...
- Managing unhelpful pressure in your creative agency: the human approach
- Paul Hutchings, founder of fox&cat, answers the questions: what does it mean to be human in 2021? Are we putting ourselves under too much pressure?...
